gsk1120212
Solid Tumors, KRAS Mutation; SOS1
Boehringer IngelheimPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Solid Tumors, KRAS Mutation; SOS1 cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
bi 1701963 Boehringer Ingelheim | Phase 1 | C |
Same molecule, other indications
gsk1120212 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →